Publications by authors named "Andrew P Garner"

Claim this Profile
A
An ALK2 inhibitor, BLU-782, prevents heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.
Alison J Davis, Natasja Brooijmans, Jason D Brubaker, Faith Stevison, Timothy P LaBranche, Andrew P Garner

Sci Transl Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Andrew P Garner, Joseph M Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Andrew P Garner, Carl U Bialucha, Elizabeth R Sprague, Joan T Garrett, Qing Sheng

Cancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase.
Richard A Norman, Anne-Kathrin Schott, David M Andrews, Jason Breed, Kevin M Foote, Andrew P Garner

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
Joanne V Allen, Catherine Bardelle, Kevin Blades, Dave Buttar, Louise Chapman, Andrew P Garner

Bioorg Med Chem Lett· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PAK1 and PAK2 have different roles in HGF-induced morphological responses.
Michael D Bright, Andrew P Garner, Anne J Ridley

Cell Signal· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROCK1 and LIMK2 interact in spread but not blebbing cancer cells.
Kerry F Shea, Claire M Wells, Andrew P Garner, Gareth E Jones

PLoS One· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.
Egle Avizienyte, Richard A Ward, Andrew P Garner

Biochem J· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The conditional kinase DeltaMEKK1:ER* selectively activates the JNK pathway and protects against serum withdrawal-induced cell death.
Sarah A Molton, Claire Weston, Kathryn Balmanno, Catherine Newson, Daniel E Todd, Andrew P Garner

Cell Signal· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumour invasion and metastasis: challenges facing drug discovery.
Paul Elvin, Andrew P Garner

Curr Opin Pharmacol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest.
Daniel E Todd, Ruth M Densham, Sarah A Molton, Kathryn Balmanno, Catherine Newson, Andrew P Garner

Oncogene· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delta MEKK3:ER* activation induces a p38 alpha/beta 2-dependent cell cycle arrest at the G2 checkpoint.
Andrew P Garner, Claire R Weston, Daniel E Todd, Kathryn Balmanno, Simon J Cook

Oncogene· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis